Menacho Román Miriam, Penedo Alonso Jose Roberto, Morales Rodríguez Audrey, Pecharromán de Las Heras Inés, Vicente Bartulos Agustina, Arribas Gómez Ignacio, Plana Farrás Nieves
Clinical Biochemistry Department. University Hospital Ramon y Cajal, Madrid, Spain.
Emergency Department. University Hospital Ramon y Cajal, Madrid, Spain.
Int J Technol Assess Health Care. 2024 Dec 10;41(1):e5. doi: 10.1017/S026646232400477X.
The assessment of technology in hospital settings is a crucial step towards ensuring the delivery of efficient, effective, and safe healthcare.
This study conducts a Hospital-Based Health Technology Assessment to evaluate the efficacy of a screening rapid test for mild Traumatic Brain Injury (mild TBI) utilizing blood biomarkers, specifically Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1). The assessment focuses on the clinical utility and performance characteristics of the proposed rapid test within a hospital setting.
The screening model was meticulously examined for its ability to accurately detect mild TBI, considering the sensitivity and specificity of GFAP and UCH-L1 as blood biomarkers. The study involved a thorough evaluation of the test's diagnostic accuracy, comparing its outcomes with established standards for mild TBI diagnosis.Results from the Hospital-Based Health Technology Assessment highlight the potential of the GFAP and UCH-L1 blood biomarker-based rapid test as an efficient screening tool for mild TBI within a hospital environment. The evidence results show that the test is highly sensitive (91 percent to 100 percent) for the prediction of acute traumatic intracranial lesions, which helps rule out injury when the result is negative. When used within 12 hours of injury in adult patients with mild TBI, this test holds promise in reducing the utilization of CT.
The findings contribute valuable insights into the feasibility and reliability of implementing this technology for timely and accurate identification of mild TBI, enhancing clinical decision making and patient care in hospital settings.
评估医院环境中的技术是确保提供高效、有效和安全医疗保健的关键一步。
本研究开展了一项基于医院的卫生技术评估，以评估利用血液生物标志物，特别是胶质纤维酸性蛋白（GFAP）和泛素C末端水解酶L1（UCH-L1）进行轻度创伤性脑损伤（轻度TBI）筛查快速检测的效果。该评估聚焦于所提议的快速检测在医院环境中的临床效用和性能特征。
考虑到GFAP和UCH-L1作为血液生物标志物的敏感性和特异性，对筛查模型准确检测轻度TBI的能力进行了细致检查。该研究全面评估了检测的诊断准确性，并将其结果与轻度TBI诊断的既定标准进行比较。基于医院的卫生技术评估结果凸显了基于GFAP和UCH-L1血液生物标志物的快速检测作为医院环境中轻度TBI有效筛查工具的潜力。证据结果表明，该检测对急性创伤性颅内病变的预测具有高度敏感性（91%至100%），当结果为阴性时有助于排除损伤。在轻度TBI成年患者受伤后12小时内使用该检测，有望减少CT的使用。
这些发现为实施该技术及时准确识别轻度TBI的可行性和可靠性提供了有价值的见解，增强了医院环境中的临床决策和患者护理。
